You’re Not Crazy to Bet on Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics, Inc. (NYSE:PLX) recovered 47.44% of its value since hitting low of $0.27. The recent move of -9.4% drop pushed the stock to close at $0.4 when trading ended on 01/11/2019. At recent session, the prices were hovering between $0.385 and $0.435. This company shares are 725% off its target price of $3.3 and the current market capitalization stands at $59.07M. The recent change has given its price a -2.98% deficit over SMA 50 and -52.04% deficit over its 52-week high. The stock witnessed -2.43% declines, -30.16% declines and -13.68% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PLX’s volatility during a week at 9.58% and during a month it has been found around 10.06%.

Protalix BioTherapeutics, Inc. (PLX) Top Holders

Institutional investors currently hold around $4 million or 9.82% in PLX stock. Look at its top three institutional owners. Renaissance Technologies Llc owns $1.3 million in Protalix BioTherapeutics, Inc., which represents roughly 2.2% of the company’s market cap and approximately 32.5% of the institutional ownership. Similar statistics are true for the second largest owner, Fosun International Ltd, which owns 2,631,400 shares of the stock are valued at $1.05 million. The third largest holder is Opaleye Management Inc., which currently holds $995 thousand worth of this stock and that ownership represents nearly 1.68% of its market capitalization.

Protalix BioTherapeutics, Inc. 13F Filings

At the end of September reporting period, 16 institutional holders increased their position in Protalix BioTherapeutics, Inc. (NYSE:PLX) by some 4,220,120 shares, 11 decreased positions by 819,013 and 14 held positions by 6,260,500. That puts total institutional holdings at 11,299,633 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 3,334,211 shares while 5 institutional investors sold out their entire positions totaling 64,033 shares.

Protalix BioTherapeutics, Inc. (NYSE:PLX) Insider Trades

Multiple company employees have indulged in significant insider trading. Protalix BioTherapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President & CEO Manor Moshe has acquired 50,000 shares of Protalix BioTherapeutics, Inc. (PLX) in trading session dated May. 16, 2017. These shares are worth $40,500 and were traded at $0.81 each. The SEC filing shows that Camber Capital Management Llc performed a sale of 2,500,000 shares. The 10% Owner disposed these shares by way of transaction on Dec. 02, 2016. The company’s shares were given away at $0.32 per share worth to an income of some $800,000 on account of Camber Capital Management Llc.

Vice President & CFO, Maimon Yossi, purchased 10,000 common shares of Protalix BioTherapeutics, Inc. (PLX) in the open market. In a transaction dated Dec. 14, 2015, the shares were bought at an average price of $0.78, giving away a sum of $7,800. After this purchase, 195,000 common shares of PLX are directly owned by the insider, with total stake valued at $78,000.

In the transaction dated Oct. 19, 2015, the great number of shares acquired came courtesy the 10% Owner; Camber Capital Management Llc added a total of 4,000,423 shares at an average price of $1, amounting to approximately $4,000,423. The insider now directly owns 26,549,577 shares worth $10,619,831.

Protalix BioTherapeutics, Inc. (PLX) Analyst Guide

Several analysts have released their opinion on Protalix BioTherapeutics, Inc. (NYSE:PLX), with 1 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.5 average brokerage recommendation.